Opendata, web and dolomites

MEDAS

MedAS: a Machine learning enabled Clinical Decision Support System to prevent prescription errors and improve patient safety

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEDAS project word cloud

Explore the words cloud of the MEDAS project. It provides you a very rough idea of what is the project "MEDAS" about.

simply    missed    burden    prescribing    depending    medaware    commercial    list    precise    learning    enter    market    8m    enabled    proof    22    intend    failed    decided    medical    machine    issue    safety    fatal    reaching    representing    errors    primary    generation    prescription    otherwise       physician    5b    trials    revenues    innovative    platform    total    health    clinical    estimate    roi    theme    big       save    decision    proven    boy    2012    first    action    wrong    financial    seize    country    statistical    managed    prototype    reducing    usa    feasibility    completely    80    adverse    retrospective    pull    2018    algorithms    alerting    israel    outliers    economic    rates    patient    care    1m    dramatically    events    solutions    medicines    drug    became    solid    utilizes    healthcare       alerts    public    electronic    identifies    team    preventable    51    error    medication    founders    cdss    8b    realising    data    21    time    generate    opportunity    accuracy    2024    started    perspectives    accidentally    medas    died    found    facilities    outcomes    analytics    nine    annual    effectiveness    constantly    deploy   

Project "MEDAS" data sheet

The following table provides information about the project.

Coordinator
MEDAWARE LTD 

Organization address
address: 10 ZARHIN ALEXANDER
city: RAANANA
postcode: 4366238
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.medaware.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDAWARE LTD IL (RAANANA) coordinator 50˙000.00

Map

 Project objective

Medication errors are the most common cause of adverse events in medication practice, although they are preventable. Only in Europe, prescription error rates range from 7.5% to 9.1% of the total managed medicines, representing a major public health issue, as some of those can even be fatal. They also represent a great economic burden to healthcare systems, with annual costs reaching €4.5B to €21.8B, depending on the country. MedAware’s founders decided to take action on the theme in 2012, when they found out that a nine-year-old boy died simply because his primary care physician accidentally selected the wrong drug, on his electronic prescribing pull-down list. By realising that current solutions completely failed to save this boy, the team started developing several proof-of-concept algorithms that became our first prototype and then MedAS (MedAware Alerting System). MedAS is an innovative patient-specific Clinical Decision Support System, that identifies and alerts on prescription errors in real-time, and with greater than 80% accuracy. It utilizes big-data analytics and advanced machine learning to identify statistical outliers and to generate precise alerts that would otherwise be missed by existing CDSS. MedAS’s effectiveness has already been proven both in retrospective trials and in real medical facilities in Israel and the USA: we improved patient safety, outcomes, and experience while dramatically reducing healthcare costs. Enabled by our next generation technology and given MedAS’s unique capabilities, we now intend to build a solid technology platform and to deploy it to the European market. The main objective of the feasibility study is to assess MedAS from technical, commercial and financial perspectives. We will seize the opportunity to enter the constantly growing CDSS market (€51.8M in Europe by 2018) with our novel technology and platform, and estimate revenues of €22.1M by 2024, with a ROI of 8.9

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

WIMUACT (2017)

TECHNOLOGY FOR THE IMPROVEMENT OF SPORTS PERFORMANCE IN NON-PROFESSIONAL CONTEXTS

Read More  

REALM (2015)

A disruptive method to free physicians from Hospital Information Systems by generating fault free patient diagnostic documents in real-time using natural language

Read More  

Enterprise BIM (2017)

Enterprise BIM digitization platform feasibility verification

Read More